Berberine sulfate inhibited RANKL-induced osteoclast formation in mouse bone marrow macrophage cultures over five days; the authors reported an IC50 of approximately 0.25 μM. A 48 h MTS control showed no viability loss through 10 μM, but its shorter duration does not exclude delayed toxicity during differentiation. [1]
Berberine sulfate in an HMGA–DNA displacement screen
Biochemical assay · Recombinant HMGA1 or HMGA2 with ATTO 680-labeled E3 DNA probe [2]
At 100 μM, compound 5 showed no clear displacement of the E3 DNA complexes in the representative EMSA. This is a qualitative negative screening result, not an IC50 or evidence of cancer-cell efficacy.
Literature-Reported Treatment Conditions
- Treatment concentration
- 100 μM
- Exposure duration
- Drug incubation 30 min after 30 min complex formation; incubations at 4 °C
- Method
- EMSA; Figure 1 uses HMGA1 1.56 pmol or HMGA2 0.78 pmol and E3 probe 0.05 pmol
- Vehicle
- 10% DMSO final in shared EMSA method
- Co-treatment
- HMGA protein plus DNA; netropsin 10 μM positive and chloramphenicol 100 μM negative controls; probe-alone and protein–probe controls
- Reported limits
- Figure 1 replicate number not stated in the read experiment description. Shared method states 0.1 pmol oligonucleotide, whereas Figure 1 caption specifies 0.05 pmol; caption conditions retained without reconciliation.
Methods and source locations
Compound reported in the paper: Berberine sulfate; Compound label in the paper: Compound 5 (BBN125)
Results apply to the reported berberine sulfate material and experimental conditions; no A14812 lot equivalence is established.
Table 1 compound 5; Figure 1 (lane 15, label #5) and caption; In Vitro Evaluation of the HMGA/DNA-Displacing Activity; Experimental Section: compound 5 and EMSA
HMGA1/E3 and HMGA2/E3 complex bands with compound 5: Representative infrared-fluorescence EMSA; no band densitometry or potency estimate extracted — Figure 1, lane 15 (#5), both HMGA panels; Table 1; results identify compounds 16, 13 and 8 as active with E3
Inhibition of osteoclast differentiation with a viability control
Cell-based study · Primary bone marrow macrophages from C57BL/6 mice differentiated with M-CSF and RANKL [1]
Berberine sulfate reduced TRAcP-positive multinucleated osteoclast formation over five days. A separate 48 h MTS control showed no decrease in BMM viability through 10 μM; its shorter duration limits exclusion of delayed cytotoxicity.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.25, 0.5, 1, 2.5, 5 and 10 μM
- Exposure duration
- 5 days for differentiation; 48 h for MTS viability control
- Method
- TRAcP staining/counting following GST-rRANKL 50 ng/mL with M-CSF
- Vehicle
- Stock dissolved in DMSO; final DMSO fraction and explicit matched-vehicle treatment are not specified in the read methods
- Co-treatment
- RANKL-induced cultures compared with RANKL-treated drug-free controls; RANKL-negative control shown
- Reported limits
- Methods define osteoclast-like cells as TRAcP-positive multinucleated cells with more than 3 nuclei. Figure 1 n = 3; exact nesting of independent cultures and wells is not fully specified.
Methods and source locations
Compound reported in the paper: Berberine sulfate; Compound label in the paper: Berberine sulfate
Results apply to the reported berberine sulfate material and experimental conditions; no A14812 lot equivalence is established.
Results 2.1; Figure 1B–E and caption; Methods 4.1–4.4 and 4.9
TRAcP-positive multinucleated osteoclast formation: Author-reported estimate, not calculated from the image; Figure 1D n = 3, data mean ± SEM per Methods 4.9; treated groups marked *** p < 0.001 versus RANKL-treated control — Results 2.1 and Discussion; Figure 1D; Methods 4.3 and 4.9
BMM metabolic viability after 48 h exposure: MTS absorbance at 490 nm; Figure 1E n = 3; control duration 48 h, not the 5-day differentiation duration — Results 2.1; Figure 1E; Methods 4.4
Suppression of RANKL-stimulated NF-κB reporter activity
Cell-based study · RAW264.7 cells stably carrying an NF-κB luciferase reporter [1]
Reporter activity was significantly reduced from 1 μM, with an author-reported approximate IC50 of 5 μM. This supports an effect on a cellular signaling readout, without identifying a directly bound molecular target.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.25, 0.5, 1, 2.5, 5 and 10 μM
- Exposure duration
- 1 h pretreatment, followed by 6 h RANKL stimulation
- Method
- NF-κB-dependent luciferase assay with GST-rRANKL 50 ng/mL
- Vehicle
- DMSO stock; final vehicle percentage not specified
- Co-treatment
- RANKL-stimulated drug-free and RANKL-negative controls shown
- Reported limits
- Figure 4A n = 6; shared statistics say mean ± SEM with at least 3 independent experiments, but well/experiment nesting is not fully resolved. No orthogonal luciferase-interference control established in the read scope.
Methods and source locations
Compound reported in the paper: Berberine sulfate; Compound label in the paper: Berberine sulfate
Results apply to the reported berberine sulfate material and experimental conditions; no A14812 lot equivalence is established.
Results 2.4; Figure 4A and caption; Methods 4.1, 4.2, 4.7 and 4.9
RANKL-induced NF-κB transcriptional luciferase activity: Results 2.4 estimate; Figure 4A shows reduction from 1 μM. Figure n = 6, mean ± SEM under Methods 4.9 — Results 2.4; Figure 4A and caption; Methods 4.7 and 4.9